Lagos State Ministry of Health/Kebbi State Ministry of Health
Lagos, Nigeria
NCT Number: NCT07200414
The goal of this clinical trial is to learn whether adding adolescent health services to routine government health programs can increase Human Papillomavirus (HPV) vaccination coverage among 9-year-old girls and improve use of other health services by adolescents in Nigeria. The main questions it aims to answer are:
Does offering an integrated package of adolescent health services increase the proportion of 9-year-old girls who receive the HPV vaccine?
Does this package increase use of other services such as reproductive health counseling, nutrition and vision screening, mental health services, and deworming among girls and boys ages 9-15 years?
Researchers will compare areas that receive the integrated package to areas that continue with the standard government services to see if the intervention improves vaccination and health service use.
Participants will:
Be surveyed about HPV vaccination and health service use before and after the program is offered.
Take part in interviews or focus groups about experiences with adolescent health services.
Be offered HPV vaccination and other adolescent health services through local health facilities.
Looking for future studies?
Notify Me9 year and older
All sexes
Interventional
Not applicable
Lagos, Nigeria
This is a mixed-methods, quasi-experimental implementation science study to evaluate the integration of adolescent health services with routine HPV vaccination in Nigeria. The study is being conducted in Lagos and Kebbi States between October 2024 and December 2025.
The intervention will leverage the routine government health system to deliver an integrated package of adolescent health services that includes HPV vaccination and additional services such as sexual and reproductive health counseling, general health check-ups, nutrition and vision screening, mental health services, deworming, and dental and oral health care.
The primary objective is to determine the effect of the integrated package on HPV vaccine coverage among 9-year-old girls. Secondary objectives include: (1) assessing changes in uptake of other adolescent health services among girls and boys aged 9-15 years, (2) examining feasibility, acceptability, and fidelity of the intervention from the perspective of adolescents, parents, providers, and policymakers, and (3) estimating incremental costs of delivering the integrated package.
The study design includes three phases: formative research, implementation, and evaluation. Baseline and endline household surveys will be conducted with parents and adolescents, supplemented by qualitative data collection (in-depth interviews (IDI), focus groups, key informant interviews (KII), and multi-informant interviews (MII)). Service delivery records and costing data from 30 health facilities will also be analyzed.
Comparison will be made between intervention and comparison local government areas to assess differences in HPV vaccine uptake and adolescent health service utilization. The study will generate evidence on strategies to improve HPV vaccination coverage and strengthen adolescent health service delivery in Nigeria.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Program managers from the Ministries of Health, and Education must:
Health service providers must:
School-based service providers such as principals, teachers and school nurses must:
Civil Society Organization (CSO) partner in the state must:
Adolescent male and female respondents:
Parents must:
Community leaders:
Exclusion criteria
Health service providers:
Adolescents:
Parents:
Delivery of an integrated package of adolescent health services through government health facilities. The package includes HPV vaccination, sexual and reproductive health counseling, general health check-ups, nutrition and vision screening, mental health support, deworming, and dental and oral health services. Implemented in intervention LGAs in Lagos and Kebbi States.
Other names: SHARP Integrated Package, Integrated Package of Adolescent Services
Routine government health services provided in comparison LGAs. Services may include HPV vaccination as per national immunization schedules and other adolescent health services delivered under existing programs, but without the integrated package.
Other names: Standard Services
Time frame: Baseline, 14 months
Human Papillomavirus Virus (HPV) vaccine coverage will be assessed among 9-year-old girls in intervention and comparison (Local Government Areas (LGAs) using baseline and endline household surveys of mother-daughter dyads, supported by administrative vaccination records from health facilities. Differences between baseline and endline coverage in intervention LGAs will be compared with those in comparison LGAs to estimate the impact of the integrated adolescent health package.
Time frame: Baseline, 14 months
Assessed using baseline and endline household surveys and service delivery data. Coverage will be calculated as the number of eligible girls who received at least one dose divided by the total eligible girls surveyed.
Time frame: Baseline, 14 months
Services may include Sexual and Reproductive Health (SRH) counseling, nutrition or vision screening, mental health services, deworming, or dental/oral care. Measured using baseline and endline household surveys and service records.
Johns Hopkins Bloomberg School of Public Health
Other
Strengthening HPV Vaccination and Adolescent Health Research Program in Nigeria (SHARP in Nigeria)
Acronym: SHARP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05334706
Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III), Communicable Diseases
L'Hospitalet de Llobregat, Catalonia, Spain
View Trial DetailsNCT07303751
Communicable Diseases, DNA Virus Infections
Freetown, Sierra Leone
View Trial DetailsNCT05453006
Cervical Cancer, Communicable Diseases
Minneapolis, Minnesota, United States
View Trial DetailsNCT00481767
Communicable Diseases, DNA Virus Infections
Dakar, Senegal
View Trial Details